The biosimilars market size has grown rapidly in recent years. It will grow from $15.86 billion in 2023 to $18.85 billion in 2024 at a compound annual growth rate (CAGR) of 18.9%. The growth observed during the historic period can be attributed to factors such as an increase in cancer prevalence, robust economic growth in emerging markets, a rise in pharmaceutical research and development (R&D) expenditure, increased healthcare spending, growing government initiatives, a strong pipeline of drugs, the cost-effectiveness of biosimilars, and an increase in patent expiration.
The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The forecasted growth is driven by factors such as the increasing prevalence of cancer, rising demand for granulocyte colony-stimulating factor (G-CSF) prophylaxis, higher healthcare expenditure, the significant potential of emerging economies, technological advancements, widespread use of biological drugs, an aging population, and improved healthcare access. Key trends in the forecast period include a focus on robust research and development for innovative drugs, emphasis on mergers and acquisitions for growth, establishment of strategic partnerships, increased investments, and utilization of artificial intelligence.
The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.
The upward trajectory of healthcare expenditures is poised to be a catalyst for the expansion of the biosimilars market. Healthcare expenditures encompass the total spending on healthcare goods and services within a specific population or healthcare system. Biosimilar products contribute to curbing healthcare expenditures by providing more cost-effective alternatives to expensive biologic drugs, thereby reducing treatment expenses for both patients and healthcare systems. For example, according to a report from the UK-based Office for National Statistics in May 2023, healthcare spending in the UK witnessed a nominal increase of 9.4% and a real increase of 9.7% between 2020 and 2021. This surge in healthcare expenditures is a driving force behind the growth of the biosimilars market.
Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.
Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.
In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.
Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd., Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd., Apotex Pty Ltd., Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoît, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)
North America was the largest region in the global biosimilars market in 2023. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.
The biosimilars market research report is one of a series of new reports that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $35.81 billion in 2028 at a compound annual growth rate (CAGR) of 17.4%. The forecasted growth is driven by factors such as the increasing prevalence of cancer, rising demand for granulocyte colony-stimulating factor (G-CSF) prophylaxis, higher healthcare expenditure, the significant potential of emerging economies, technological advancements, widespread use of biological drugs, an aging population, and improved healthcare access. Key trends in the forecast period include a focus on robust research and development for innovative drugs, emphasis on mergers and acquisitions for growth, establishment of strategic partnerships, increased investments, and utilization of artificial intelligence.
The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.
The upward trajectory of healthcare expenditures is poised to be a catalyst for the expansion of the biosimilars market. Healthcare expenditures encompass the total spending on healthcare goods and services within a specific population or healthcare system. Biosimilar products contribute to curbing healthcare expenditures by providing more cost-effective alternatives to expensive biologic drugs, thereby reducing treatment expenses for both patients and healthcare systems. For example, according to a report from the UK-based Office for National Statistics in May 2023, healthcare spending in the UK witnessed a nominal increase of 9.4% and a real increase of 9.7% between 2020 and 2021. This surge in healthcare expenditures is a driving force behind the growth of the biosimilars market.
Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.
Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.
In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.
Major companies operating in the biosimilars market report are Amgen, Pfizer, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Biocon, Celltrion, Inc., Coherus Biosciences, Elli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd., Abbott India Limited, bioMérieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Mylan, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd., Apotex Pty Ltd., Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, HARMONIE MEDICAL SERVICE Saint-Benoît, INSULET FRANCE SAS Paris, Microgen, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Emisphere Technologies, Inc., Enteris BioPharma, Allena Pharmaceuticals, Abbvie, Johnson & Johnson, Biogen Inc., Aché, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)
North America was the largest region in the global biosimilars market in 2023. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.
The biosimilars market research report is one of a series of new reports that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Biosimilars Market Characteristics3. Biosimilars Market Trends and Strategies32. Global Biosimilars Market Competitive Benchmarking33. Global Biosimilars Market Competitive Dashboard34. Key Mergers and Acquisitions in the Biosimilars Market
4. Biosimilars Market - Macro Economic Scenario
5. Global Biosimilars Market Size and Growth
6. Biosimilars Market Segmentation
7. Biosimilars Market Regional and Country Analysis
8. Asia-Pacific Biosimilars Market
9. China Biosimilars Market
10. India Biosimilars Market
11. Japan Biosimilars Market
12. Australia Biosimilars Market
13. Indonesia Biosimilars Market
14. South Korea Biosimilars Market
15. Western Europe Biosimilars Market
16. UK Biosimilars Market
17. Germany Biosimilars Market
18. France Biosimilars Market
19. Italy Biosimilars Market
20. Spain Biosimilars Market
21. Eastern Europe Biosimilars Market
22. Russia Biosimilars Market
23. North America Biosimilars Market
24. USA Biosimilars Market
25. Canada Biosimilars Market
26. South America Biosimilars Market
27. Brazil Biosimilars Market
28. Middle East Biosimilars Market
29. Africa Biosimilars Market
30. Biosimilars Market Competitive Landscape and Company Profiles
31. Biosimilars Market Other Major and Innovative Companies
35. Biosimilars Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Biosimilars Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Type: Monoclonal Antibodies; Insulin; Erythropoietin; Granulocyte-Colony Stimulating Factor; Other Hormones; Others
2) By Product: Recombinant Non-glycosylated Proteins; Recombinant Glycosylated Proteins
3) By Application: Oncology; Chronic and Autoimmune Diseases; Growth Hormone Deficiency; Infectious Diseases; Other Applications
Key Companies Mentioned: Amgen; Pfizer; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Amgen
- Pfizer
- Novartis AG
- Samsung Bioepis Co., Ltd.
- Viatris
- Biocon
- Celltrion, Inc.
- Coherus Biosciences
- Elli Lilly and Company
- Dr. Reddy's Laboratories
- Roche India Pvt Ltd
- Abbott India Limited
- bioMérieux India
- Becton Dickinson Private Limited
- Danaher Corporation
- Wuxi biologics
- shanghai Henlius biotech
- Innovent Biologics
- Hisun Pharma
- 3SBio
- Beijing ShuangLu Pharmaceuticals
- Qilu Pharmaceutical
- Mylan
- Kyowa Hakko Kirin
- Takeda
- Mitsubishi Tanabe
- AGC Biologics
- Bio-Thera
- Sandoz Pty Ltd
- Apotex Pty Ltd
- Cadila Pharmaceuticals
- BiosanaPharma
- GlaxoSmithKline
- AstraZeneca
- Bayer
- Merck
- Boehringer Ingelheim
- Sanofi
- Fresenius Kabi
- Napp Pharmaceuticals
- Mundipharma Deutschland GmbH & Co. KG
- HARMONIE MEDICAL SERVICE Saint-Benoît
- INSULET FRANCE SAS Paris
- Microgen
- Geropharm
- Valenta
- NovaMedica
- SynBio
- Rani Therapeutics
- Emisphere Technologies, Inc.
- Enteris BioPharma
- Allena Pharmaceuticals
- Abbvie
- Johnson & Johnson
- Biogen Inc.
- Aché
- Eurofarma
- Teva Pharmaceuticals
- Oramed Pharmaceuticals
- Entera Bio
- Julphar
- Hikma Pharmaceuticals
- BIOPHARMA-MEA
- NeoTX
- AID Genomics Limited
- Altis Biologics
- Cipla Medpro South Africa
- Next Biosciences
- Viome
- Inqaba Biotechnical Industries (Pty)
Methodology
LOADING...
